This report takes a closer look at QuidelOrtho Corp. (QDEL). The company is navigating a shift in its revenue mix, with COVID-19 testing declining but core diagnostic segments showing resilience. Recent FDA clearance for its cardiac assay adds a new catalyst to watch as investors assess its financial guidance and market performance.
Recent Developments
The VITROS hs Troponin I Assay represents a significant addition to QuidelOrtho's VITROS platform, enabling U.S. laboratories to deliver faster and more accurate cardiac diagnostics. Commercial rollout is expected later this year, providing a new revenue stream and reinforcing the company's reputation for innovation. CEO Brian Blaser highlighted this launch as part of QuidelOrtho's broader strategy to expand margins and accelerate innovation across its global portfolio.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.